Behavior of HIV in Viral Environments (B-HIVE)
HIV 在病毒环境中的行为 (B-HIVE)
基本信息
- 批准号:10508443
- 负责人:
- 金额:$ 628.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-22 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:AIDS/HIV problemAcquired Immunodeficiency SyndromeBehaviorBinding SitesBiologicalBiophysicsCapsidCell CommunicationCell NucleusCellsCharacteristicsChemicalsCollaborationsCommunicationComputational BiologyCytoplasmDiseaseEducation and OutreachEnvironmentEvolutionFundingGenetic TranscriptionGenomeGoalsHIVHIV IntegraseHIV-1Human ResourcesInfectionInfrastructureIntegration Host FactorsJointsLeadershipMentorsModelingMolecularNuclearNuclear AccidentsNucleic AcidsNucleosome Core ParticlePathogenesisPositioning AttributeProductionProteinsPublicationsRNARNA-Directed DNA PolymeraseResearchResearch PersonnelRoleScientific Advances and AccomplishmentsShapesSiteSynthesis ChemistryTestingTimeUnited States National Institutes of HealthUniversitiesViralViral PackagingVirusVirus ReplicationWashingtonexperiencegene productinhibitorinsightintegration sitemembernext generationnovelnovel therapeutic interventionorganizational structureparticleprogramsprotein complexsmall moleculesmall molecule inhibitorsuccesstraffickingviral RNAvirology
项目摘要
ABSTRACT, OVERVIEW
The Behavior of HIV In Viral Environments (B-HIVE) Center has been formed to further the understanding of
HIV-1 and HIV-1/cellular host factor macromolecular interactions within distinct cellular environments, which
shape the HIV replication cycle. With the limited size of HIV’s RNA genome, it is no surprise that many of the
same gene products end up performing different functions in different cellular environments at different times
during replication. These various HIV-1-cell host factor interactions promote the cellular pathogenesis, and
ultimately disease, characteristic of HIV-1/AIDS. All members have joined the B-HIVE Center with the common
goal to collaboratively investigate the dynamic HIV-1 and HIV-1/cellular host factor macromolecular interactions
within distinct cellular environments that occur during infection. The B-HIVE Center will capitalize on well-
established collaborations between top HIV researchers and scientific accomplishments that provide the
rationale to ask new and challenging questions and will be informed by the former HIVE Center (HIV Interaction
and Viral Evolution), an organizational structure proven to be effective at not only HIV-1 research, but also by
exemplary communication to training, and outreach activities. The B-HIVE team of highly collaborative
investigators includes well-established experts in structural, biophysical, chemical, and computational biology,
virology, and synthetic chemistry. Only as a Center do the researchers have the necessary combined expertise
and critical mass to effectively study the dynamic and mechanistic implications of macromolecular interactions
of HIV and cellular host factors within distinct cellular environments. The overall aims of the B-HIVE are organized
around three complementary Projects that focus on specific stages of the viral replication cycle:
Project 1. Dynamic HIV-1 core interactions with host factors and inhibitors from cytoplasm to nucleus.
Aim 1. To discover and characterize novel, dynamic interactions between HIV-1 CA and host cell during virus
ingress. Aim 2. To characterize interactions of novel small molecule inhibitors with distinct sites on HIV-1 CA.
Project 2. Structural dynamics of HIV-1 nuclear trafficking, integration, and transition to transcription.
Aim1. Elucidate dynamic HIV-1 core-host cell interactions crucial for nuclear trafficking, uncoating, and
integration. Aim 2. Define the structural and dynamic nuclear events underlying HIV-1 integration site selection.
Aim 3. Determine the interplay between integration site and transcriptional latency.
Project 3. The dynamics of HIV-1 packaging and assembly.
Aim 1. Study the mechanism of HIV-1 RNA genome packaging and the proteins complexed with HIV-1 RNA.
Aim 2. Probe the cellular dynamics of the interactions between HIV-1 Gag and identified cellular factors that
alter HIV-1 production. Aim 3. Elucidate the dynamics of model Gag assembly and particle formation.
抽象,概述
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stefan G Sarafianos其他文献
Biochemical mechanism of clinical resistance to rilpivirine
- DOI:
10.1186/1471-2334-12-s1-p94 - 发表时间:
2012-05-04 - 期刊:
- 影响因子:3.000
- 作者:
Kamalendra Singh;Devendra K Rai;Bechan Sharma;Eleftherios Michailidis;Emily M Ryan;Kayla B Matzek;Maxwell D Leslie;Ariel N Hagedorn;Hong-Tao Xu;Mark A Wainberg;Bruno Marchand;Stefan G Sarafianos - 通讯作者:
Stefan G Sarafianos
The Combination of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Rilpivirine Shows Synergistic Anti-HIV-1 Activ- ity In Vitro
4-乙炔基-2-氟-2-脱氧腺苷与利匹韦林的组合在体外显示出协同抗 HIV-1 活性
- DOI:
- 发表时间:
2012 - 期刊:
- 影响因子:0
- 作者:
Atsuko Hachiya;Bruno Marchand;Eleftherios Michailidis;Eiichi N Kodama;Michael A Parni- ak;Hiroaki Mitsuya;Shinichi Oka;Stefan G Sarafianos - 通讯作者:
Stefan G Sarafianos
Stefan G Sarafianos的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stefan G Sarafianos', 18)}}的其他基金
Discovery of SARS-CoV-2 antivirals using a replicon assay
使用复制子测定发现 SARS-CoV-2 抗病毒药物
- 批准号:
10522048 - 财政年份:2022
- 资助金额:
$ 628.9万 - 项目类别:
Behavior of HIV in Viral Environments (B-HIVE)
HIV 在病毒环境中的行为 (B-HIVE)
- 批准号:
10650864 - 财政年份:2022
- 资助金额:
$ 628.9万 - 项目类别:
Discovery of SARS-CoV-2 antivirals using a replicon assay
使用复制子测定发现 SARS-CoV-2 抗病毒药物
- 批准号:
10673119 - 财政年份:2022
- 资助金额:
$ 628.9万 - 项目类别:
Taking aim at HBV eradication using novel NRTIs and Capsid effectors
使用新型 NRTI 和衣壳效应物消灭 HBV
- 批准号:
9918244 - 财政年份:2017
- 资助金额:
$ 628.9万 - 项目类别:
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV
野生型和多重耐药艾滋病毒的超强抑制剂
- 批准号:
9605989 - 财政年份:2017
- 资助金额:
$ 628.9万 - 项目类别:
Taking aim at HBV eradication using novel NRTIs and Capsid effectors
使用新型 NRTI 和衣壳效应物消灭 HBV
- 批准号:
9605893 - 财政年份:2017
- 资助金额:
$ 628.9万 - 项目类别:
Reverse Transcriptase Multi-Class Drug Resistance and Rilpivirine Susceptibility in Diverse HIV-1 Subtypes
不同 HIV-1 亚型中的逆转录酶多类耐药性和利匹韦林敏感性
- 批准号:
9140626 - 财政年份:2016
- 资助金额:
$ 628.9万 - 项目类别:
Development of HIV capsid-targeting antivirals that affect immune response by modulating capsid stability and have improved resistance profiles
开发 HIV 衣壳靶向抗病毒药物,通过调节衣壳稳定性影响免疫反应并改善耐药性
- 批准号:
10437037 - 财政年份:2016
- 资助金额:
$ 628.9万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 628.9万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 628.9万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 628.9万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 628.9万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 628.9万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 628.9万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 628.9万 - 项目类别:














{{item.name}}会员




